Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

P-Cure Collaborates with RaySearch on P-Cure’s Gantry-Less Seated Proton System Designed to Fit within Linac Vaults


The partnership will enable users of the P-Cure Proton Therapy System, which features in-room integrated diagnostic quality vertical CT, synchrotron-delivered pencil beam proton scanning, and a robotic convertible chair, to also utilize the automation and workflow support provided by RayCare2, the next generation oncology information system, as well as the features for adaptive radiation therapy.

P-Cure prides itself on the commitment to a patient centric approach. This commitment manifest itself in designing a proton system starting with the patient first and foremost. “We believe that we have designed a proton system that improves the patient experience, provides treatment and clinical benefits, offers the easiest and fastest opportunity for oncology centers to expand their treatment options to include proton therapy, and to do so in the least expensive manner. The evolving collaboration with RaySearch further helps to turn our commitment into a reality,” says Dr. Michael Marash, CEO of P-Cure.

Johan LVf, founder and CEO, RaySearch says: “We are proud to work with a company that is ushering in a new era of proton therapy. P-Cure is a pioneer in the development of upright radiation therapy and the ability to provide a proton system in a regular Linac room has great potential to expand proton therapy.”

Dr. Marash, says: “Our partnership with RaySearch, the world leader in treatment planning, will play an important role in our pioneering efforts to bring the benefits of proton therapy to help a far larger world-wide patient body. I am happy that we have now taken our partnership to the next level and I believe our technologies have great potential together.”

About P-Cure:

P-Cure Ltd., an Israel-based company, develops and supplies the most compact Proton Therapy solution for the targeted treatment of cancer with radiation. Founded in 2007, P-Cure has developed a comprehensive patient centric proton therapy solution with clinical benefits and financial advantages. The P-Cure mission is to provide proton therapy with greater treatment precision, enhanced clinical outcomes, and expanded treatment options. By significantly reducing the capital and operating costs, P-Cure expands the availability of proton therapy to all cancer care institutions and new facility developers worldwide.The P-Cure commitment is to put the patient first. For more information please visit: http://www.p-cure.com

About RaySearch:

RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.

RaySearch software is used by over 800 clinics in more than 40 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com.

*Subject to regulatory clearance in some markets

Media Contact

Stephen JACOBS, P-Cure, 1 9173468619, [email protected], p-cure.com

SOURCE P-Cure

Parkinson's Disease Psychosis Market is Likely to Increase at a Steady Growth Rate by 2032, Estimates DelveInsight | Key Companies Working to Develop Therapies – Vanda, Kyowa Kirin, Sage, Athira, Aptinyx, CogState, AgeneBio



The dynamics of the Parkinson’s disease psychosis market are anticipated to change in the coming years owing to the improvement in diagnosis methodologies, rising awareness of the disease, incremental healthcare spending worldwide, and the expected launch of emerging therapies LAS VEGAS,…

Premia Spine Announces New Technology Add-On Payment for TOP™ System


In the TOPS US clinical trial, the mean age of patients was 64 years, thus indicating a sizable addressable market for the NTAP program.

Ron Sacher, CEO of Premia Spine commented, “We are honored by the recognition of CMS. TOPS™ has proven its ability to provide both clinical excellence and healthcare economic advantage to patients, providers, and payers. The NTAP program is an example of forward-thinking policy that aligns incentives so that patients receive the best short-term and long-term care.”

A publication in the Journal of Health Economics and Outcomes Research, “A Prospective Study of Lumbar Facet Arthroscopy in the Treatment of Degenerative Spondylolisthesis and Stenosis: Early Cost-Effective Assessment from the Total Posterior Spine System (TOPS) IDE Study” confirmed the cost-effectiveness and economic benefit of the TOPS System versus TLIF fusion for patients suffering from spondylolisthesis and spinal stenosis.

The data from the prospective randomized study was analyzed by Neuronomics, an independent professional corporation focusing on healthcare economic analyses. Its findings demonstrate that, even at a premium of $4,000 over the cost of a TLIF implant, TOPS™ still achieves cost-effectiveness at a willingness-to-pay threshold of $100,000 within one-year after surgery. Furthermore, TOPS becomes the dominant strategy when data is examined at two years and beyond. From the societal perspective, TOPS is even more highly cost-effective at one year and dominant at two years and beyond.

The paper, led by author Jared Ament, MD, a neurosurgeon at the Neurosurgery & Spine Group, Los Angeles, states, “TOPS™ appears to be a highly cost-effective surgical modality compared with TLIF as a motion-preserving, non-fusion alternative for the treatment of grade 1 spondylolisthesis with lumbar spinal stenosis. Since the TOPS System yields greater QOL [quality of life] at a lower total cost over time, it deserves serious attention.”

Media Contact

Peter Wehrly, Premia Spine, 1 (303) 324-4983, [email protected], https://premiaspine.us

Peter Wehrly, Premia Spine, 1 (303) 324-4983, [email protected], https://premiaspine.us

SOURCE Premia Spine

3B Scientific adquiere Wallcur



HAMBURGO, Alemania, 2 de octubre de 2023 /PRNewswire/ — 3B Scientific, fabricante y comercializador líder de productos de simulación médica y modelos anatómicos para educación sanitaria, anuncia hoy la adquisición de Wallcur LLC, un destacado proveedor de productos de simulación…

3B Scientific erwirbt Wallcur



HAMBURG, Deutschland, 2. Oktober 2023 /PRNewswire/ — 3B Scientific, ein führender Hersteller und Vermarkter von medizinischen Simulationsprodukten und anatomischen Modellen für die Ausbildung im Gesundheitswesen, gibt heute die Übernahme von Wallcur LLC bekannt, einem führenden Anbieter…

The Biden Administration Waves White Flag in FGA v. HHS Lawsuit on Drug Price Transparency


In response to its resounding legal victory in the federal lawsuit FGA v. HHS, FGA released the following statement:

“When the Biden administration decided to take the side of health insurers and drug manufacturers, FGA decided to take the side of patients and their families. We stood up to the federal behemoth in court, and we won,” said Tarren Bragdon, president and CEO at the Foundation for Government Accountability. “Because of this victory, millions of Americans will have transparent access to the information they need to make informed health care decisions.”

Washington gridlock can make major policy advancements difficult to come by. But FGA is committed to finding ways to make a positive impact across the country and keep the American Dream alive. That’s why we fight, and that’s why winning matters so much,” added Bragdon.

The TiC rule aims to provide patients with critical information needed to make informed health decisions, improving health care quality by promoting free-market solutions through price transparency. The Biden administration’s refusal to allow agencies to enforce this rule without first following the formal process of withdrawing and amending the rule, which requires a lengthy and transparent notice-and-comment period, violated federal law.

“The Biden administration broke the law when they prohibited agencies from enforcing the drug price transparency rule, and they knew it. That’s why they caved in response to FGA’s lawsuit by formally reversing their non-enforcement policy on drug price transparency before a federal judge compelled them to do so,” said Stewart Whitson, legal director at FGA. “Whenever government officials willfully ignore the law, it’s crucial they be held accountable. But holding the administration accountable takes resources and skill that those suffering from this refusal often lack. That’s where FGA comes in. FGA is proud to step up on behalf of everyday Americans and use the power of the courts to hold elected officials and government bureaucrats accountable, especially when their actions harm patients and their families.”

“When FGA engages in a legal battle, we fight to win. Now that the Biden administration has surrendered their position of non-enforcement, and our objective has been fully achieved, it is time to drop our lawsuit and shift our focus to the next worthy battle,” added Whitson.

NARRATIVE BACKGROUND:

In 2019, The Trump administration announced the Transparency in Coverage (TiC) effort to create administrative rules requiring increased transparency and upfront disclosure of health care costs, including prescription drug pricing. The rule was finalized in 2020 and the drug price transparency provision was set to take effect on January 1, 2022. But before the rule could take effect, the Biden administration used an FAQ guidance document to block enforcement of the Transparency in Coverage rule.

In response, FGA filed a federal lawsuit against the U.S. Departments of Health and Human Services, Labor, and Treasury for prohibiting the enforcement of the drug price transparency rule. Due to pressure from FGA’s lawsuit, the Departments issued updated FAQ guidance reversing their previous position of non-enforcement.

For more information about FGA’s legal efforts, filing, and active lawsuits, click here.

The Foundation for Government Accountability (FGA) is a non-profit, multi-state think tank that promotes public policy solutions to create opportunities for every American to experience the American Dream. To learn more, visit TheFGA.org.

Media Contact

Adam Gibbs, Foundation for Government Accountability, 239.244.8808 x 165, [email protected], www.theFGA.org

Twitter

SOURCE Foundation for Government Accountability